BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adashek JJ, Breunig JJ, Posadas E, Bhowmick NA, Ellis L, Freedland SJ, Kim H, Figlin R, Gong J. First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been? Drugs 2022. [PMID: 35175588 DOI: 10.1007/s40265-022-01683-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zarrabi KK, Handorf E, Miron B, Zibelman MR, Anari F, Ghatalia P, Plimack ER, Geynisman DM. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma. Oncologist 2023;28:157-64. [PMID: 36200791 DOI: 10.1093/oncolo/oyac195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Voss MH. Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell Carcinoma. J Clin Oncol 2022;:JCO2200834. [PMID: 35679526 DOI: 10.1200/JCO.22.00834] [Reference Citation Analysis]